{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:13:12Z","timestamp":1776813192790,"version":"3.51.2"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T00:00:00Z","timestamp":1539561600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13000-018-0758-0","type":"journal-article","created":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T16:11:57Z","timestamp":1539619917000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["KRAS mutation in secondary malignant histiocytosis arising from low grade follicular lymphoma"],"prefix":"10.1186","volume":"13","author":[{"given":"Sarah M.","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleodor A.","family":"Andea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Behdad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dittmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6651-8617","authenticated-orcid":false,"given":"Juehua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,15]]},"reference":[{"key":"758_CR1","volume-title":"WHO publications center","author":"SHCE Swerdlow","year":"2008","unstructured":"Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO classification of Tumours of Haematopoietic and lymphoid tissues. In: WHO publications center; 2008."},{"issue":"4","key":"758_CR2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00428-015-1814-8","volume":"467","author":"MR Ambrosio","year":"2015","unstructured":"Ambrosio MR, De Falco G, Rocca BJ, et al. Langerhans cell sarcoma following marginal zone lymphoma: expanding the knowledge on mature B cell plasticity. Virchows Arch. 2015;467(4):471\u201380.","journal-title":"Virchows Arch"},{"issue":"6","key":"758_CR3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.4103\/1947-2714.114172","volume":"5","author":"W Chen","year":"2013","unstructured":"Chen W, Jaffe R, Zhang L, et al. Langerhans cell sarcoma arising from chronic lymphocytic lymphoma\/small lymphocytic leukemia: lineage analysis and BRAF V600E mutation study. N Am J Med Sci. 2013;5(6):386\u201391.","journal-title":"N Am J Med Sci"},{"issue":"12","key":"758_CR4","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.1182\/blood-2007-11-124792","volume":"111","author":"AL Feldman","year":"2008","unstructured":"Feldman AL, Arber DA, Pittaluga S, et al. Clonally related follicular lymphomas and histiocytic\/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. Blood. 2008;111(12):5433\u20139.","journal-title":"Blood"},{"issue":"6","key":"758_CR5","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1309\/AJCPWQ0I0DGXBMHO","volume":"132","author":"CR Fraser","year":"2009","unstructured":"Fraser CR, Wang W, Gomez M, et al. Transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma to interdigitating dendritic cell sarcoma: evidence for transdifferentiation of the lymphoma clone. Am J Clin Pathol. 2009;132(6):928\u201339.","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"758_CR6","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/modpathol.2011.102","volume":"24","author":"H Shao","year":"2011","unstructured":"Shao H, Xi L, Raffeld M, et al. Clonally related histiocytic\/dendritic cell sarcoma and chronic lymphocytic leukemia\/small lymphocytic lymphoma: a study of seven cases. Mod Pathol. 2011;24(11):1421\u201332.","journal-title":"Mod Pathol"},{"issue":"5","key":"758_CR7","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3109\/10428191003699845","volume":"51","author":"E Wang","year":"2010","unstructured":"Wang E, Hutchinson CB, Huang Q, et al. Histiocytic sarcoma arising in indolent small B-cell lymphoma: report of two cases with molecular\/genetic evidence suggestive of a 'transdifferentiation' during the clonal evolution. Leuk Lymphoma. 2010;51(5):802\u201312.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"758_CR8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/PAS.0b013e3182098799","volume":"35","author":"E Wang","year":"2011","unstructured":"Wang E, Papalas J, Hutchinson CB, et al. Sequential development of histiocytic sarcoma and diffuse large b-cell lymphoma in a patient with a remote history of follicular lymphoma with genotypic evidence of a clonal relationship: a divergent (bilineal) neoplastic transformation of an indolent B-cell lymphoma in a single individual. Am J Surg Pathol. 2011;35(3):457\u201363.","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"758_CR9","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1097\/PAS.0b013e318283099f","volume":"37","author":"DS West","year":"2013","unstructured":"West DS, Dogan A, Quint PS, et al. Clonally related follicular lymphomas and Langerhans cell neoplasms: expanding the spectrum of transdifferentiation. Am J Surg Pathol. 2013;37(7):978\u201386.","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"758_CR10","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","volume":"116","author":"G Badalian-Very","year":"2010","unstructured":"Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919\u201323.","journal-title":"Blood"},{"issue":"12","key":"758_CR11","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1182\/blood-2012-06-429597","volume":"120","author":"F Sahm","year":"2012","unstructured":"Sahm F, Capper D, Preusser M, et al. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood. 2012;120(12):e28\u201334.","journal-title":"Blood"},{"issue":"6","key":"758_CR12","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","volume":"131","author":"MR Green","year":"2018","unstructured":"Green MR. Chromatin modifying gene mutations in follicular lymphoma. Blood. 2018;131(6):595\u2013604.","journal-title":"Blood"},{"issue":"5","key":"758_CR13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1080\/15592294.2017.1282587","volume":"12","author":"K Korfi","year":"2017","unstructured":"Korfi K, Ali S, Heward JA, Fitzgibbon J. Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations. Epigenetics. 2017;12(5):370\u20137.","journal-title":"Epigenetics"},{"issue":"9","key":"758_CR14","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1182\/blood-2012-09-457283","volume":"121","author":"MR Green","year":"2013","unstructured":"Green MR, Gentles AJ, Nair RV, et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood. 2013;121(9):1604\u201311.","journal-title":"Blood"},{"issue":"1","key":"758_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","volume":"6","author":"L Pasqualucci","year":"2014","unstructured":"Pasqualucci L, Khiabanian H, Fangazio M, et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014;6(1):130\u201340.","journal-title":"Cell Rep"},{"issue":"17","key":"758_CR16","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/blood-2012-05-378596","volume":"120","author":"AF Ward","year":"2012","unstructured":"Ward AF, Braun BS, Shannon KM. Targeting oncogenic Ras signaling in hematologic malignancies. Blood. 2012;120(17):3397\u2013406.","journal-title":"Blood"},{"issue":"6","key":"758_CR17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrc1097","volume":"3","author":"M Malumbres","year":"2003","unstructured":"Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3(6):459\u201365.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"758_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrc2109","volume":"7","author":"S Schubbert","year":"2007","unstructured":"Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7(4):295\u2013308.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"758_CR19","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood.V96.5.1633","volume":"96","author":"F Anjuere","year":"2000","unstructured":"Anjuere F, del Hoyo GM, Martin P, Ardavin C. Langerhans cells develop from a lymphoid-committed precursor. Blood. 2000;96(5):1633\u20137.","journal-title":"Blood"},{"issue":"6","key":"758_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1470-2045(05)70211-4","volume":"6","author":"AL Feldman","year":"2005","unstructured":"Feldman AL, Berthold F, Arceci RJ, et al. Clonal relationship between precursor T-lymphoblastic leukaemia\/lymphoma and Langerhans-cell histiocytosis. Lancet Oncol. 2005;6(6):435\u20137.","journal-title":"Lancet Oncol"},{"issue":"7","key":"758_CR21","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1038\/leu.2012.27","volume":"26","author":"AH Schmitt-Graeff","year":"2012","unstructured":"Schmitt-Graeff AH, Duerkop H, Vollmer-Kary B, et al. Clonal relationship between langerhans cell histiocytosis and myeloid sarcoma. Leukemia. 2012;26(7):1707\u201310.","journal-title":"Leukemia"},{"issue":"6","key":"758_CR22","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1097\/PAS.0b013e31819287b8","volume":"33","author":"W Chen","year":"2009","unstructured":"Chen W, Lau SK, Fong D, et al. High frequency of clonal immunoglobulin receptor gene rearrangements in sporadic histiocytic\/dendritic cell sarcomas. Am J Surg Pathol. 2009;33(6):863\u201373.","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"758_CR23","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1182\/blood-2004-07-2839","volume":"105","author":"YH Hou","year":"2005","unstructured":"Hou YH, Srour EF, Ramsey H, Dahl R, Broxmeyer HE, Hromas R. Identification of a human B-cell\/myeloid common progenitor by the absence of CXCR4. Blood. 2005;105(9):3488\u201392.","journal-title":"Blood"},{"issue":"12","key":"758_CR24","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/S0145-2126(02)00009-7","volume":"26","author":"M Magni","year":"2002","unstructured":"Magni M, Di Nicola M, Carlo-Stella C, et al. Identical rearrangement of immunoglobulin heavy chain gene in neoplastic Langerhans cells and B-lymphocytes: evidence for a common precursor. Leuk Res. 2002;26(12):1131\u20133.","journal-title":"Leuk Res"},{"issue":"11","key":"758_CR25","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma","year":"1997","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The non-Hodgkin's lymphoma classification project. Blood. 1997;89(11):3909\u201318.","journal-title":"Blood"},{"issue":"10","key":"758_CR26","doi-asserted-by":"publisher","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","volume":"112","author":"MR Green","year":"2015","unstructured":"Green MR, Kihira S, Liu CL, et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci U S A. 2015;112(10):E1116\u201325.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"758_CR27","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1182\/blood-2016-08-733469","volume":"129","author":"I Garcia-Ramirez","year":"2017","unstructured":"Garcia-Ramirez I, Tadros S, Gonzalez-Herrero I, et al. Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice. Blood. 2017;129(19):2645\u201356.","journal-title":"Blood"},{"issue":"9","key":"758_CR28","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/nsmb.2642","volume":"20","author":"M Delvecchio","year":"2013","unstructured":"Delvecchio M, Gaucher J, Aguilar-Gurrieri C, Ortega E, Panne D. Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation. Nat Struct Mol Biol. 2013;20(9):1040\u20136.","journal-title":"Nat Struct Mol Biol"},{"issue":"14","key":"758_CR29","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1038\/sj.onc.1205283","volume":"21","author":"LW Yuan","year":"2002","unstructured":"Yuan LW, Giordano A. Acetyltransferase machinery conserved in p300\/CBP-family proteins. Oncogene. 2002;21(14):2253\u201360.","journal-title":"Oncogene"},{"issue":"17","key":"758_CR30","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/blood-2012-05-378596","volume":"120","author":"AF Ward","year":"2012","unstructured":"Ward AF, Braun BS, Shannon KM. Targeting oncogenic Ras signaling in hematologic malignancies. Blood. 2012;120(17):3397\u2013406.","journal-title":"Blood"},{"issue":"2","key":"758_CR31","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3324\/haematol.2013.096248","volume":"99","author":"JP Vaque","year":"2014","unstructured":"Vaque JP, Martinez N, Batlle-Lopez A, et al. B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. Haematologica. 2014;99(2):222\u201331.","journal-title":"Haematologica"},{"issue":"10","key":"758_CR32","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1073\/pnas.1121343109","volume":"109","author":"JG Lohr","year":"2012","unstructured":"Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012;109(10):3879\u201384.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"758_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002197","volume":"13","author":"R Kridel","year":"2016","unstructured":"Kridel R, Chan FC, Mottok A, et al. Histological transformation and progression in follicular lymphoma: a clonal evolution study. PLoS Med. 2016;13(12):e1002197.","journal-title":"PLoS Med"},{"issue":"2","key":"758_CR34","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/ng.2856","volume":"46","author":"J Okosun","year":"2014","unstructured":"Okosun J, Bodor C, Wang J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014;46(2):176\u201381.","journal-title":"Nat Genet"},{"issue":"5","key":"758_CR35","first-page":"844","volume":"10","author":"HM Clark","year":"1996","unstructured":"Clark HM, Yano T, Sander C, Jaffe ES, Raffeld M. Mutation of the ras genes is a rare genetic event in the histologic transformation of follicular lymphoma. Leukemia. 1996;10(5):844\u20137.","journal-title":"Leukemia"},{"issue":"12","key":"758_CR36","doi-asserted-by":"publisher","first-page":"7259","DOI":"10.1073\/pnas.1137463100","volume":"100","author":"KS Elenitoba-Johnson","year":"2003","unstructured":"Elenitoba-Johnson KS, Jenson SD, Abbott RT, et al. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci U S A. 2003;100(12):7259\u201364.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"758_CR37","unstructured":"Shanmugam V, Sholl L, Fletcher CD, Hornick JL. RAS\/MAPK Pathway Activation Defines a Common Molecular Subtype of Histiocytic Sarcoma. United States and Canadian Academy of Pathologists. Vancouver BC, CA; 2018."},{"issue":"4","key":"758_CR38","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1182\/blood-2017-02-770149","volume":"130","author":"T Kamata","year":"2017","unstructured":"Kamata T, Giblett S, Pritchard C. KRAS(G12D) expression in lung-resident myeloid cells promotes pulmonary LCH-like neoplasm sensitive to statin treatment. Blood. 2017;130(4):514\u201326.","journal-title":"Blood"},{"issue":"6","key":"758_CR39","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1183\/13993003.01677-2015","volume":"47","author":"S Mourah","year":"2016","unstructured":"Mourah S, How-Kit A, Meignin V, et al. Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis. Eur Respir J. 2016;47(6):1785\u201396.","journal-title":"Eur Respir J"},{"issue":"2","key":"758_CR40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.canlet.2009.01.022","volume":"283","author":"C Montagut","year":"2009","unstructured":"Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 2009;283(2):125\u201334.","journal-title":"Cancer Lett"},{"issue":"2","key":"758_CR41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1365-2141.2011.08915.x","volume":"156","author":"G Badalian-Very","year":"2012","unstructured":"Badalian-Very G, Vergilio JA, Degar BA, Rodriguez-Galindo C, Rollins BJ. Recent advances in the understanding of Langerhans cell histiocytosis. Br J Haematol. 2012;156(2):163\u201372.","journal-title":"Br J Haematol"},{"key":"758_CR42","doi-asserted-by":"crossref","unstructured":"Zarnegar S, Durham BH, Khattar P, et al. Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. Pediatr Blood Cancer. 2018;65(1).","DOI":"10.1002\/pbc.26699"},{"issue":"10","key":"758_CR43","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1182\/blood-2014-05-577361","volume":"124","author":"NA Brown","year":"2014","unstructured":"Brown NA, Furtado LV, Betz BL, et al. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood. 2014;124(10):1655\u20138.","journal-title":"Blood"},{"issue":"1","key":"758_CR44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12943-017-0690-z","volume":"16","author":"S Heritier","year":"2017","unstructured":"Heritier S, Helias-Rodzewicz Z, Chakraborty R, et al. New somatic BRAF splicing mutation in Langerhans cell histiocytosis. Mol Cancer. 2017;16(1):115.","journal-title":"Mol Cancer"},{"issue":"19","key":"758_CR45","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1182\/blood-2014-05-577825","volume":"124","author":"R Chakraborty","year":"2014","unstructured":"Chakraborty R, Hampton OA, Shen X, et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014;124(19):3007\u201315.","journal-title":"Blood"},{"issue":"20","key":"758_CR46","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1182\/blood-2016-08-735795","volume":"128","author":"B Thakral","year":"2016","unstructured":"Thakral B, Khoury JD. Histiocytic sarcoma: secondary neoplasm or \u201ctransdifferentiation\u201d in the setting of B-acute lymphoblastic leukemia. Blood. 2016;128(20):2475.","journal-title":"Blood"},{"issue":"9839","key":"758_CR47","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358\u201365.","journal-title":"Lancet"},{"issue":"10","key":"758_CR48","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1093\/annonc\/mdx339","volume":"28","author":"PB Chapman","year":"2017","unstructured":"Chapman PB, Robert C, Larkin J, et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol. 2017;28(10):2581\u20137.","journal-title":"Ann Oncol"},{"issue":"2","key":"758_CR49","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107\u201314.","journal-title":"N Engl J Med"},{"issue":"25","key":"758_CR50","doi-asserted-by":"publisher","first-page":"20785","DOI":"10.18632\/oncotarget.4750","volume":"6","author":"M Morkel","year":"2015","unstructured":"Morkel M, Riemer P, Bl\u00e4ker H, Sers C. Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. Oncotarget. 2015;6(25):20785\u2013800.","journal-title":"Oncotarget"},{"issue":"7404","key":"758_CR51","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nature11156","volume":"486","author":"S Misale","year":"2012","unstructured":"Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(7404):532\u20136.","journal-title":"Nature"},{"issue":"16","key":"758_CR52","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1001\/jama.2010.1535","volume":"304","author":"W De Roock","year":"2010","unstructured":"De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of kras p.g13d mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010;304(16):1812\u201320.","journal-title":"JAMA"},{"issue":"4","key":"758_CR53","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.clcc.2012.02.003","volume":"11","author":"P Gajate","year":"2012","unstructured":"Gajate P, Sastre J, Bando I, et al. Influence of KRAS p.G13D mutation in patients with metastatic colorectal Cancer treated with Cetuximab. Clin Colorectal Cancer. 2012;11(4):291\u20136.","journal-title":"Clin Colorectal Cancer"},{"issue":"11","key":"758_CR54","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov. 2014;13(11):828\u201351.","journal-title":"Nat Rev Drug Discov"},{"issue":"7623","key":"758_CR55","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nature19771","volume":"538","author":"J Kim","year":"2016","unstructured":"Kim J, McMillan E, Kim HS, et al. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Nature. 2016;538(7623):114\u20137.","journal-title":"Nature"},{"key":"758_CR56","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/asheducation.V2015.1.565.3919688","volume":"2015","author":"O Abla","year":"2015","unstructured":"Abla O, Weitzman S. Treatment of Langerhans cell histiocytosis: role of BRAF\/MAPK inhibition. Hematology Am Soc Hematol Educ Program. 2015;2015:565\u201370.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"11","key":"758_CR57","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd.2016.139","volume":"15","author":"JML Ostrem","year":"2016","unstructured":"Ostrem JML, Shokat KM. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat Rev Drug Discov. 2016;15(11):771\u201385.","journal-title":"Nat Rev Drug Discov"},{"key":"758_CR58","first-page":"5","volume":"8","author":"JM Foster","year":"2015","unstructured":"Foster JM, Oumie A, Togneri FS, et al. Cross-laboratory validation of the OncoScan(R) FFPE assay, a multiplex tool for whole genome tumour profiling. BMC Med Genet. 2015;8:5.","journal-title":"BMC Med Genet"},{"issue":"7\u20138","key":"758_CR59","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.cancergen.2012.06.005","volume":"205","author":"Y Wang","year":"2012","unstructured":"Wang Y, Cottman M, Schiffman JD. Molecular inversion probes: a novel microarray technology and its application in cancer research. Cancer Genet. 2012;205(7\u20138):341\u201355.","journal-title":"Cancer Genet"},{"key":"758_CR60","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.humpath.2017.10.014","volume":"71","author":"MD Carter","year":"2018","unstructured":"Carter MD, Gaston D, Huang W-Y, et al. Genetic profiles of different subsets of Merkel cell carcinoma show links between combined and pure MCPyV-negative tumors. Hum Pathol. 2018;71:117\u201325.","journal-title":"Hum Pathol"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-018-0758-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13000-018-0758-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-018-0758-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T01:19:41Z","timestamp":1662254381000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-018-0758-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,15]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["758"],"URL":"https:\/\/doi.org\/10.1186\/s13000-018-0758-0","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,15]]},"assertion":[{"value":"16 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Exemption was received from the Northwestern University Institutional Review Board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"78"}}